IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet

The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade

IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032. Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024.

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

STOCKHOLM , Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023. CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans.

Medivir to present at the Carlsquare Equity Research Investor Day

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indications halted – – Cash runway expected to extend into second quarter 2026 – – Reduction in workforce of approximately 22 percent – MOUNTAIN VIEW, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that it will focus its resources in two strategic areas: (i) treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies, and (ii) treating autoimmune diseases using IgM T cell engager antibodies.

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

STOCKHOLM , Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted.  The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm.

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

STOCKHOLM , Nov. 27, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has finalized the development of an updated formulation of fostrox, suitable for commercial manufacture. HCC is a potentially life-threatening form of liver cancer and the third leading cause of cancer-related death worldwide.

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

STOCKHOLM , Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023. CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.

Medivir to present at the Redeye Life Science Day

STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET. CEO Jens Lindberg will present and answer questions about the latest developments and the company's future plans.

Medivir to present at the Erik Penser Bank Company Event

The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.

IGM Biosciences Announces Third Quarter 2023 Financial Results

STOCKHOLM , Nov. 13, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical data from the ongoing phase 1b/2a study of in fostroxacitabine bralpamide (fostrox) in combination with Lenvima® (lenvatinib) in hepatocellular carcinoma (HCC), will be presented at the ASCO Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco, USA. The abstract, titled "First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC)" will be presented by Dr. Maria Reig, Director of the Barcelona Clinic Liver Cancer (BCLC) and the Liver Oncology Unit at the Hospital Clinic of Barcelona in Spain.

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences:

IGM Biosciences to Present at Two Upcoming Investor Conferences

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks.

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

STOCKHOLM , Oct. 23, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024. According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board.

Nomination Committee of Medivir appointed

STOCKHOLM , Oct. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company's board member Anette Lindqvist has informed the board of directors that she is leaving her position due to personal reasons.  "We respect Anette's decision and at the same time want to thank her for her meritorious efforts.

Change in Medivir's Board of Directors

Early and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-up Durable clinical benefit, median time to progression (to date) ~4.5 months with >50% of patients still on treatment Consistently good safety and tolerability profile STOCKHOLM , Oct. 5, 2023 /PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that all patients in the ongoing phase 2a study in advanced hepatocellular carcinoma (HCC) has now dosed at least two treatment cycles and the treatment continues to show very promising clinical benefit. The study evaluates safety and efficacy with the candidate drug fostrox in combination with Lenvima® in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, effective October 3, 2023. Dr. Loberg has served as a member of the IGM Biosciences Board of Directors since 2015 and as Chairman of the Board since 2018.

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

STOCKHOLM , Sept. 11, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

STOCKHOLM , Sept. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the International Liver Cancer Association (ILCA) Annual Meeting, September 7-9 in Amsterdam.

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 9:30 a.m. EDT.

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Central review of the 6 patients in phase 1b dose escalation part was performed In these 6 patients, complete response was recorded in 1 patient, partial response in 2 patients, and stable disease in 2 patients read by an independent radiologist using mRECIST The interim data from phase 1b further strengthens the previously reported promising safety and efficacy data STOCKHOLM , Sept. 4, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today promising interim safety and efficacy data from its ongoing phase 1b/2a study of first-in-class candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC) patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.

News for IGM Biosciences Inc Stock (IGMS)